First Drug Shows Promise Against Alzheimer's Tau Tangles

Scientists just achieved something that has eluded researchers for decades: slowing Alzheimer's progression by targeting tau, the toxic protein tangles that destroy brain cells.

Biogen's experimental drug diranersen made history in May 2026 by becoming the first treatment in a Phase 2 study to both reduce tau buildup and improve cognitive outcomes in people with early Alzheimer's disease. The CELIA trial enrolled 416 patients with mild cognitive impairment or early dementia.

The results were remarkable. Patients receiving the treatment showed significant reductions in tau proteins in their spinal fluid and brain scans across all doses tested. More importantly, they experienced slower mental decline, particularly those receiving the lowest dose every 24 weeks.

The drug works differently from other Alzheimer's treatments currently on the market. While existing medications target amyloid plaques outside brain cells, diranersen tackles tau tangles both inside and outside neurons. It stops tau production at its source by targeting the genetic instructions that tell cells to make the protein.

Dr. Jeff Cummings, a brain sciences professor at the University of Nevada, Las Vegas, called the findings an important advance for the field. "This provides the first evidence that reducing tau may meaningfully impact disease progression," he said.

The treatment was administered through spinal injections, and safety tests showed it was generally well tolerated. Side effects were comparable across different dose groups, though higher doses showed slightly more serious adverse events.

Why This Inspires

More than six million Americans live with Alzheimer's, and that number continues to grow as the population ages. For families watching loved ones slip away, each scientific advance carries profound meaning.

This breakthrough represents a fundamentally new approach to fighting the disease. By proving that reducing tau can slow cognitive decline, researchers have validated an entirely new treatment pathway. The FDA recognized diranersen's promise by granting it Fast Track designation in 2025, which speeds the review process.

Biogen plans to move forward with larger registrational trials that could eventually lead to FDA approval. The company will present detailed findings at the Alzheimer's Association International Conference in 2026, where the broader medical community can analyze the data.

The study's success matters beyond just one drug. It demonstrates that tau reduction is a viable strategy, potentially opening doors for other tau-targeting therapies in development. Every validated approach brings researchers closer to treatments that could one day stop Alzheimer's entirely.

For patients and families navigating early Alzheimer's diagnoses today, these results offer something precious: scientific evidence that meaningful progress is possible.